{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:45Z","timestamp":1786786125115,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06852-1","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:33:32Z","timestamp":1780000412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed\/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi"],"prefix":"10.1007","volume":"105","author":[{"given":"Mario","family":"Ballerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ravano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ballotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Loseto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"1","key":"6852_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","volume":"143","author":"F Lansigan","year":"2020","unstructured":"Lansigan F, Horwitz SM, Pinter-Brown LC et al (2020) Outcomes for relapsed and refractory peripheral T-Cell lymphoma patients after Front-Line therapy from the COMPLETE registry. Acta Haematol 143(1):40\u201350. https:\/\/doi.org\/10.1159\/000500666","journal-title":"Acta Haematol"},{"key":"6852_CR2","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.24571","volume":"92","author":"F Zaja","year":"2017","unstructured":"Zaja F, Tabanelli V, Agostinelli C et al (2017) CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: possible biomarkers for novel targeted therapies? Am. J Hematol 92:E1\u2013E2. https:\/\/doi.org\/10.1002\/ajh.24571","journal-title":"J Hematol"},{"key":"6852_CR3","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2017) World Health Organization classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition, Volume 2. Lyon: IARC"},{"issue":"2","key":"6852_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-016-2877-6","volume":"96","author":"F Qi","year":"2017","unstructured":"Qi F, Dong M, He X et al (2017) Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Ann Hematol Feb 96(2):245\u2013251. https:\/\/doi.org\/10.1007\/s00277-016-2877-6Epub 2016 Nov 17","journal-title":"Ann Hematol Feb"},{"issue":"11","key":"6852_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","volume":"94","author":"BB Park","year":"2015","unstructured":"Park BB, Kim WS, Suh C et al (2015) Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol Nov 94(11):1845\u20131851. https:\/\/doi.org\/10.1007\/s00277-015-2468-yEpub 2015 Aug 8","journal-title":"Ann Hematol Nov"},{"key":"6852_CR6","doi-asserted-by":"publisher","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. Jul 6;394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","DOI":"10.1016\/S0140-6736(19)31240-1"},{"issue":"8","key":"6852_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136(8):936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"6852_CR8","doi-asserted-by":"publisher","unstructured":"Bride KL, Vincent TL, Im SY et al (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 131(9):995\u2013999 https:\/\/doi.org\/10.1182\/blood-2017-07-794214","DOI":"10.1182\/blood-2017-07-794214"},{"issue":"21","key":"6852_CR9","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT et al (2024) Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood 144(21):2237\u20132247 https:\/\/doi.org\/10.1182\/blood.2024024493","journal-title":"Blood"},{"issue":"8","key":"6852_CR10","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","volume":"103","author":"H Shi","year":"2024","unstructured":"Shi H, Yang F, Cao M et al (2024) Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: Single-arm, open-label, phase I study. Ann Hematol Aug 103(8):2993\u20133004. https:\/\/doi.org\/10.1007\/s00277-024-05775-z","journal-title":"Ann Hematol Aug"},{"issue":"1","key":"6852_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00277-024-06118-8","volume":"104","author":"SY Kaya","year":"2025","unstructured":"Kaya SY, Vatani M, Akil R et al (2025) A complete response with daratumumab, venetoclax, Azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia\/lymphoma patient. Ann Hematol Jan 104(1):829\u2013833. https:\/\/doi.org\/10.1007\/s00277-024-06118-8","journal-title":"Ann Hematol Jan"},{"issue":"3","key":"6852_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/biomedicines12030512","volume":"12","author":"G Castellanos","year":"2024","unstructured":"Castellanos G, Pardo L, L\u00f3pez A et al (2024) Daratumumab and nelarabine treatment as salvage therapy for T-lymphoblastic lymphoma: a case report. Biomedicines 12(3):512 https:\/\/doi.org\/10.3390\/biomedicines12030512","journal-title":"Biomedicines"},{"issue":"1","key":"6852_CR13","doi-asserted-by":"publisher","first-page":"e76733","DOI":"10.7759\/cureus.76733","volume":"17","author":"SZ Davis","year":"2025","unstructured":"Davis SZ, Cui W, Snyder J, Lufti F (2025) Complete remission of plasmablastic lymphoma with daratumumab and a mild regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (Mini-CHOP). Cureus 17(1):e76733 https:\/\/doi.org\/10.7759\/cureus.76733","journal-title":"Cureus"},{"issue":"1","key":"6852_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","volume":"15","author":"H Huang","year":"2021","unstructured":"Huang H, Zhu J, Yao M et al (2021) Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol Feb 15(1):25. https:\/\/doi.org\/10.1186\/s13045-020-01020-y","journal-title":"J Hematol Oncol Feb"},{"key":"6852_CR15","doi-asserted-by":"publisher","unstructured":"Ma X, Wong SW, Zhou P et al (2018) Daratumumab binds to mobilized CD34\u2009+\u2009cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol 7:27. https:\/\/doi.org\/10.1186\/s40164-018-0119-4. eCollection 2018","DOI":"10.1186\/s40164-018-0119-4"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06852-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:21Z","timestamp":1786785621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6852"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06852-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and it has been approved by the Institutional Etichs Commitee of each participating centre.","order":1,"name":"Ethics","label":"Ethical","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent prior to study enrollment, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Comitato Etico Unico Regionale c\/o Azienda Regionale di Coordinamento per la Salute (ARCS) via Pozzuolo, 330 33100 UDINE.","order":3,"name":"Ethics","label":"Approval of the study","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2022 M. B.: no disclosure \u2022E. L.: no disclosure \u2022 E. R. : no disclosure \u2022\tJ. R.: no disclosure\u2022\tC. P.: no dislosure \u2022\tA. A.: no dislosure \u2022\tF. C.: BeOne, Sobi, Roche, Astrazeneca, Incyte , Lilly, Abbvie, Pierre Fabre, Kyte, Novartis, Gentili (Speaker Bureau\/or Advisory Board) \u2022\tL. B.: no disclosure \u2022\tG. L.: Janssen Cilag, Roche, Italfarmaco, Incyte, Abbvie, Gilead, Takeda, BeOne, Astrazeneca \u2022\tA. E.: no disclosure\u2022\tV. T.: no disclosure \u2022\tF. Z.: Janssen Cilag, Abbvie, Gilead, Lilly, Amgen, Grifols, Sanofi, Takeda, Novartis, BeOne, Incyte, Astrazeneca.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is registered with ClinicalTrials.gov (NCT04251065, first posted on 31 January 2020). The complete study protocol is available from the corresponding author upon request.","order":5,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"346"}}